๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Efficacy and safety of viscum fraxini-2 in advanced hepatocellular carcinoma: a phase II study

โœ Scribed by Mohamed A. Ebrahim; Hend A. El-Hadaad; Omyma A. Alemam; Salah A. Keshta

Publisher
Springer
Year
2010
Tongue
English
Weight
332 KB
Volume
9
Category
Article
ISSN
1610-1979

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase 2 study of cetuximab in patients w
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
โœ Andrew X. Zhu; Keith Stuart; Lawrence S. Blaszkowsky; Alona Muzikansky; Donald P ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 131 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor (EGFR) and ligand expression is frequently seen in hepatocellular carcinoma (HCC). A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC. ## METHODS.